Your Health, We Care
Release date: 2024-08-06 13:45:51 Recommended: 170
Exkivity, also known as Mobocertinib, is a novel targeted drug that offers hope to patients with specific types of lung cancer. The launch of Exkivity marks a major step forward in the field of targeted therapies for lung cancer.
Exkivity is an innovative, oral, small molecule tyrosine kinase inhibitor (TKI) specifically developed for the treatment of patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertion mutations. This specific type of EGFR mutation is relatively uncommon in patients with NSCLC, but Exkivity provides an effective treatment option for these patients by precisely inhibiting EGFR and its associated signaling pathways.
It can target EGFR mutations at the molecular level, inhibit the growth and spread of tumor cells, and block the growth signal of tumor cells by inhibiting specific tyrosine kinases, such as EGFR, HER2, and HER4, so as to achieve the purpose of inhibiting tumor growth. Its potent and specific inhibition has enabled Exkivity to demonstrate promising efficacy in the treatment of patients with associated NSCLC, thereby prolonging survival and improving quality of life.
Patients should also be aware of the possible adverse effects when using Exkivity, and should strictly follow the doctor's guidance and undergo regular physical examinations when receiving Exkivity.
The high price of the original drug of Exkivity (about 37,000 yuan per box) often becomes an unbearable financial burden for many families. Many patients turn to more cost-effective alternatives, with the Lao version of Exkivity being one of the most popular options.
Lucius, a top pharmaceutical company in Laos, is known for its outstanding achievements in the field of anti-cancer drugs, focusing on the development and production of high-quality anti-cancer drugs. The company strictly followed the 100% control standard with the original drug and successfully launched the Laos Lucius version of Exkivity, which successfully passed the strict approval of the Lao Drug Regulatory Bureau, ensuring the compliance and safety of the product.
Exkivity produced by Lucius Pharmaceutical is consistent with the original drug of Takeda Pharmaceutical of Japan in terms of composition, drug dosage, packaging specifications, and quality standards, achieving a high degree of equivalence. However, in terms of price, the Lucius version of Exkivity has shown great advantages, and its price is only about one-tenth of the original drug, which greatly reduces the financial pressure on patients.
【Warm tips】When using Exkivity, please learn more about the indications, dosage, adverse reactions, and precautions of Exkivity. If in doubt, consult a doctor or pharmacist promptly.
